title: The ROC 'n' role of the multiplex assay for early detection of ovarian cancer.
abstract: In order to overcome the significant mortality associated with ovarian cancer, a highly sensitive and specific screening test is urgently needed. CA125 is used to assess response to chemotherapy, detect recurrence, and distinguish malignant from benign disease; however, this marker is elevated in only 50-60% of stage I ovarian cancers, making it inadequate for early detection of malignancy. In this Practice Point, we discuss Visintin et al.'s attempt to validate a novel multiplex assay that uses a panel of six serum biomarkers -- leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA125. The study included 362 healthy controls and 156 patients with newly diagnosed ovarian cancer. The final model yielded 95.3% sensitivity, 99.4% specificity, a positive predictive value of 99.3% and a negative predictive value of 99.2%. These results indicate potential utility of this assay for early detection of ovarian cancer, although further validation is needed in a sample set representative of the general population.
authors.affiliation: Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center Unit, Houston, TX 77230-1439, USA.
authors.forename: Alpa M
authors.initials: AM
authors.lastname: Nick
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood